RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen Sells 20,000 Shares

RxSight, Inc. (NASDAQ:RXSTGet Free Report) CFO Shelley B. Thunen sold 20,000 shares of RxSight stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $49.90, for a total value of $998,000.00. Following the completion of the sale, the chief financial officer now directly owns 8,402 shares in the company, valued at $419,259.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $50.42 on Wednesday. RxSight, Inc. has a 1 year low of $16.15 and a 1 year high of $58.21. The business has a 50 day simple moving average of $50.96 and a two-hundred day simple moving average of $38.61. The firm has a market capitalization of $1.87 billion, a PE ratio of -35.26 and a beta of 1.22.

RxSight (NASDAQ:RXSTGet Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.10. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. The business had revenue of $28.58 million during the quarter, compared to analyst estimates of $28.60 million. Equities research analysts expect that RxSight, Inc. will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wells Fargo & Company raised RxSight from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $31.00 to $42.00 in a research note on Wednesday, December 13th. Stifel Nicolaus boosted their price objective on RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Oppenheimer boosted their price objective on RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. boosted their price objective on RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC boosted their price objective on RxSight from $53.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $49.63.

Get Our Latest Analysis on RXST

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. RiverPark Advisors LLC boosted its position in shares of RxSight by 70.0% during the fourth quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock valued at $27,000 after buying an additional 275 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in shares of RxSight in the fourth quarter valued at approximately $27,000. BluePath Capital Management LLC purchased a new stake in shares of RxSight in the third quarter valued at approximately $32,000. Lazard Asset Management LLC purchased a new stake in shares of RxSight in the second quarter valued at approximately $70,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of RxSight by 788.0% in the third quarter. Tower Research Capital LLC TRC now owns 3,046 shares of the company’s stock valued at $85,000 after purchasing an additional 2,703 shares during the period. Hedge funds and other institutional investors own 78.78% of the company’s stock.

About RxSight

(Get Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Further Reading

Insider Buying and Selling by Quarter for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.